Growth hormone deficiency after treatment of acromegaly: A randomized, placebo-controlled study of growth hormone replacement

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 2, 2010, Pages 567-577

  Miller, Karen K ^a   Wexler, Tamara ^a   Fazeli, Pouneh ^a   Gunnell, Lindsay ^a   Graham, Gwenda J ^a   Beauregard, Catherine ^a   Hemphill, Linda ^a   Nachtigall, Lisa ^a   Loeffler, Jay ^a   Swearingen, Brooke ^a   Biller, Beverly M K ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C REACTIVE PROTEIN; ESTROGEN; FIBRINOGEN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTHRALGIA; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; ESTROGEN THERAPY; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INJECTION SITE DISCOMFORT; MALE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 76149125135     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1611     Document Type: Article

References (62)

1. Barreto-Filho JA, Alcântara MR, Salvatori R, Barreto MA, Sousa AC, Bastos V, Souza AH, Pereira RM, Clayton PE, Gill MS, Aguiar-Oliveira MH 2002 Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia. J Clin Endocrinol Metab 87:2018-2023
2. Binnerts A, Deurenberg P, Swart GR, Wilson JH, Lamberts SW 1992 Body composition in growth hormone-deficient adults. Am J Clin Nutr 55:918-923
3. De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA 1992 Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab 75:833-837
4. Devin JK, Blevins Jr LS, Verity DK, Chen Q, Bloodworth Jr JR, Covington J, Vaughan DE 2007 Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab 92:3633-3639
5. Gomez JM, Sahun M, Vila R, Domenech P, Catalina P, Soler J, Badimon L 2006 Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf) 64:632-639
6. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129:195-200
7. Sesmilo G, Miller KK, Hayden D, Klibanski A 2001 Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 86:5774-5781
8. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J 1995 The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80:153-159
9. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A 1996 Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883-890
10. Beauregard C, Utz AL, Schaub AE, Nachtigall L, Biller BM, Miller KK, Klibanski A 2008 Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:2063-2071
11. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A 2000 Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111-122
12. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P 2004 Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89:2192-2199
13. Ronchi CL, Giavoli C, Ferrante E, Verrua E, Bergamaschi S, Ferrari DI, Corbetta S, Montefusco L, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P 2009 Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. Eur J Endocrinol 161:37-42
14. Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Ståhl E, Monson JP, Westberg B, Wilton P, Wüster C 2002 Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. Eur J Endocrinol 146:67-74
15. Norrman LL, Johannsson G, Sunnerhagen KS, Svensson J 2008 Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab 93:2531-2538
16. van der Klaauw AA, Bax JJ, Roelfsema F, Stokkel MP, Bleeker GB, Biermasz NR, Smit JW, Romijn JA, Pereira AM 2009 Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary 12:339-346
17. Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML, Zimmerman D 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children-2003 update. Endocr Pract 9:64-76
18. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML 2002 Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 87:2067-2079
19. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ 2002 Which patients do not require aGH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87:477-485
20. Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G, Utz AL, Biller B, Nachtigall L, Loeffler J, Swearingen B, Klibanski A, Miller KK 2009 Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94:2471-2477
21. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S 2004 Growth hormone-releasing hormone in HIV-infected men with lipodystrophy. JAMA 292:210-218
22. Cunningham JJ 1990 Calculation of energy expenditure from indirect calorimetry: assessment of the Weir equation. Nutrition 6:222-223
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
24. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M 2000 Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63
25. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ 2000 Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410
26. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wíren L 1999 The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8:373-383
27. Holmes SJ, McKenna SP, Doward LC, Hunt SM, Shalet SM 1995 Development of a questionnaire to access the quality of life of adults with growth hormone deficiency. Endocrinol Metab 2:63-69
28. Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ 2006 Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 188:346-353
29. Lavie CJ, Milani RV 2006 Adverse psychological and coronary risk profiles in young patients with coronary artery disease and benefits of formal cardiac rehabilitation. Arch Intern Med 166:1878-1883
30. Denninger JW, Papakostas GI, Mahal Y, Merens W, Alpert JE, Nierenberg AA, Yeung A, Fava M 2006 Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics 47:348-352
31. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E 1993 Anger attacks in unipolar depression, part 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry 150:1158-1163
32. Fava GA, Kellner R, Perini GI, Fava M, Michelacci L, Munari F, Evangelisti LP, Grandi S, Bernardi M, Mastrogiacomo I 1983 Italian validation of the Symptom Rating Test (SRT) and Symptom Questionnaire (SQ). Can J Psychiatry 28:117-123
33. Kellner R 1987 A symptom questionnaire. J Clin Psychiatry 48: 268-274
34. Ware JE, Snow KK, Kosinski M, Gandek B1993 SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center
35. McHorney CA, Ware Jr JE, Raczek AE 1993 The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247-263
36. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO, Vance ML 2004 Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men andwomenin a double-blind, randomized, placebocontrolled trial. J Clin Endocrinol Metab 89:2048-2056
37. Després JP, Lemieux I, Prud'homme D 2001 Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322: 716-720
38. Lamarche B 1998 Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 9:473-481
39. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C 1990 Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497-511
40. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino Sr RB, O'Donnell CJ 2007 Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116:39-48
41. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S 1987 Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59
42. Biermasz NR, van Dulken H, Roelfsema F 2000 Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:2476-2482
43. Murray RD, Peacey SR, Rahim A, Toogood AA, Thorner MO, Shalet SM 2001 The diagnosis of growth hormone deficiency(GHD) in successfully treated acromegalic patients. Clin Endocrinol (Oxf) 54:37-44
44. van der Klaauw AA, Pereira AM,van Thiel SW, Smit JW, Corssmit EP, Biermasz NR, Frolich M, Iranmanesh A, Veldhuis JD, Roelfsema F, Romijn JA 2006 GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24h GH secretion. Eur J Endocrinol 154:851-858
45. Bjork S, Jonsson B, Westphal O, Levin JE 1989 Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl 356:55-59; discussion 60, 73-74
46. McGauley GA 1989 Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 356:70-72; discussion 73-74
47. Colao A 2008 The GH/IGF axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 69:347-358
48. Vitale G, Pivonello R, Auriemmo RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A 2005 Hypertension in acomegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 63:470-476
49. Borson-Chazot F, Serusclat A, Kalfallah Y, Ducottet X, Sassolas G, Bernard S, Labrousse F, Pastene J, Sassolas A, Roux Y, Berthezène F 1999 Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 84:1329-1333
50. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN 1999 Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84:453-457
51. Colao A, Di Somma C, Rota F, Pivonello R, Savanelli MC, Spiezia S, Lombardi G 2005 Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 90:2056-2062
52. Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G 2001 Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 54:515-524
53. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F 2005 Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90:2731-2739
54. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F 2004 Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369-5376
55. Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E, Niskanen L, Reunanen A, Stenman UH 2006 Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91:3891-3896
56. van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, van Aken MO, Havekes B, Pereira AM, Pijl H, Smit JW, Romijn JA 2008 Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf) 69:775-784
57. Attanasio AF, Shavrikova EP, Blum WF, Shalet SM 2005 Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood. J Clin Endocrinol Metab 90:4525-4529
58. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D 1998 The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab 83:107-116
59. Holmes SJ, Shalet SM 1995 Factors influencing the desire for longterm growth hormone replacement in adults. Clin Endocrinol (Oxf) 43:151-157
60. McGauley GA, Cuneo RC, Salomon F, Sonksen PH 1990 Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res 33(Suppl 4):52-54
61. Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, Karlsson FA 1995 Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GHin a placebo-controlled 21-month trial. J Clin Endocrinol Metab 80:3585-3590
62. Baum HB, Katznelson L, Sherman JC, Biller BM, Hayden DL, Schoenfeld DA, Cannistraro KE, Klibanski A 1998 Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 83:3184-3189